Luke Miels, GSK chief commercial officer

Lend­ing a hand to a biotech in trou­ble, GSK drops $75M cash to add late-stage an­tibi­ot­ic to port­fo­lio

GSK likes to take pride in be­ing one of the few Big Phar­ma play­ers still ac­tive in an­tibi­otics R&D. And that means keep­ing tabs on what the field has to of­fer.

In a move to beef up the late-stage pipeline, GSK is li­cens­ing a late-stage an­tibi­ot­ic can­di­date from Spero Ther­a­peu­tics. In do­ing so, it’s com­ing to the res­cue of a strug­gling biotech that’s crum­bled in the wake of an FDA re­jec­tion and raised doubts about its abil­i­ty to car­ry on.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.